Skip to main content

Advertisement

Log in

T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes

Annals of Hematology Aims and scope Submit manuscript

Abstract

A single-center retrospective was performed with consecutive de novo BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients who received TKI-containing therapy between January 2010 and December 2018 to review the incidence, treatment, and outcome of the T315I mutation. A total of 38 (18%) patients harbored the T315I mutation in this period. According to the type of salvage therapy, patients were divided into subgroups of hematopoietic stem cell transplantation (HSCT) recipients (n = 9) and HSCT nonrecipients (n = 29). In the latter subgroup, there were 7 patients who newly acquired the T315I mutation after HSCT, and the median time was 10.8 months. In addition to these 7 cases, 5 out of 22 patients were managed with chimeric antigen receptor (CAR) T cells and ponatinib. There were 4 patients in the HSCT recipient subgroup who were treated with CAR-T cells or ponatinib before HSCT. The complete molecular remission (CMR) and recurrence rate of HSCT recipients were both 67%, and the median recurrence time was 3.6 months. A better overall survival (OS) was observed in the HSCT recipient subgroup than in the HSCT nonrecipient subgroup (median of 12.3 months vs 3.3 months, respectively; p = 0.004). Compared with patients who were not bridging to HSCT, the patients who were treated with CAR-T cells and/or ponatinib and bridged to HSCT tended to have a better OS (median of 3.3 months vs 13.3, respectively; p = 0.09). In conclusion, the outcomes in ALL patients with the T315I BCR-ABL1 mutation were poor. A better OS can be achieved through ponatinib, CAR-T cells, and bridging to HSCT, but it also has a higher risk of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 110(2):727–734

    Article  CAS  Google Scholar 

  2. Soverini S, De Benedittis C, Papayannidis C et al (2014) Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era. Cancer. 120(7):1002–1009

    Article  CAS  Google Scholar 

  3. Pallera A, Altman JK, Berman E et al. NCCN guidelines insights: chronic myeloid leukemia, Version 1.2017. J Natl Compr Cancer Netw 2016; 14 (12): 1505–1512

  4. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo D, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N (2017) NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017. J Natl Compr Cancer Netw 15(9):1091–1102

    Article  CAS  Google Scholar 

  5. Nicolini FE, Basak GW, Kim D, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry L, Kantarjian HM, Cortes JE (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 123(15):2875–2880

    Article  CAS  Google Scholar 

  6. Yang F, Yang X, Bao X et al (2019) Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation. Leuk Lymphoma:1–8

  7. Seymour JF, Kim DW, Rubin E et al (2014) A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J 4:e238

    Article  CAS  Google Scholar 

  8. Sumi M, Sato K, Kaiume H et al (2017) Second cord blood transplantation and interferon-α maintenance therapy for relapsed Ph+ acute lymphoblastic leukemia with the T315I mutation. Leuk Lymphoma 58(8):2005–2007

    Article  Google Scholar 

  9. Nicolini FE, Mauro MJ, Martinelli G et al (2009) Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 114(26):5271–5278

    Article  CAS  Google Scholar 

  10. How GF, Müller MC, Lim LC (2012) Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient. Leuk Res 36(1):e20–e21

    Article  CAS  Google Scholar 

  11. Wang D, Pan H, Wang Y (2016) T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib. Leuk Lymphoma 58(7):1–3

    CAS  Google Scholar 

  12. Zhang H, He X, Ni D et al (2019) How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study. J Biomol Struct Dyn 5:1–12

    Google Scholar 

  13. Xu P, Guo D, Shao X et al (2017) Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors. Oncotargets Ther 10:4731–4738

    Article  Google Scholar 

  14. Spyridonidis A, Labopin M, Schmid C et al (2012) Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 26(6):1211–1217

    Article  CAS  Google Scholar 

  15. Ortí G, Sanz J, García-Cadenas I et al (2018) Analysis of relapse post transplant in acute leukemia, a comparative on second allogeneic hematopoietic cell transplant and donor lymphocyte infusions. Exp Hematol 62:24–32

    Article  Google Scholar 

  16. Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N, Tei C (2008) Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol 88(3):331–335

    Article  CAS  Google Scholar 

  17. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R (2009) Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 33(1):174–177

    Article  CAS  Google Scholar 

  18. Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, di Raimondo F, Milone G (2018) Long-term molecular remission achieved by antibody anti-CD22 and ponatinib in a patient affected by Ph’+ acute lymphoblastic leukemia relapsed after second allogeneic hematopoietic stem cell transplantation: a case report. Chemotherapy. 63(4):220–224

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Conception and design: Ting Shi.

Data collecting: Ting Shi and Mixue Xie.

Statistical analysis: Lixia Zhu and Xueying Li.

Manuscript writing: Ting Shi and Mixue Xie.

Article reviewing: Wanzhuo Xie and Xiujin Ye.

Final approval of the manuscript: Ting Shi, Mixue Xie, Lixia Zhu, Xueying Li, Wanzhuo Xie, and Xiujin Ye.

Corresponding author

Correspondence to Ye Xiujin.

Ethics declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of informed consent

Informed consent was obtained from the patient included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ting, S., Mixue, X., Lixia, Z. et al. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes. Ann Hematol 99, 829–834 (2020). https://doi.org/10.1007/s00277-020-03949-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-03949-z

Keywords

Navigation